The Hague, May 4 (EFE).-The European Medicines Agency on Tuesday began a rolling review of the first vaccine submitted for EU market authorization by a Chinese company.
The EU regulator’s human medicines committee (CHMP) will base the review of Sinovac’s COVID-19 Vaccine (Vero Cell) Inactivated on preliminary results from laboratory and clinical studies.
“These studies suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease,” the EMA said in a statement.
The EU applicant for the vaccine was Life’On S.r.l.
The Sinovac jab contains an inactivated form of the Sars-CoV-2 virus that causes Covid-19.
Four vaccines currently have EU market authorization, including Pfizer/Biontech, AstraZeneca, Moderna and Janssen, a single-dose shot. EFE